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Background and purpose: A substantial reduction of uncertainties in clinical brachytherapy should result
in improved outcome in terms of increased local control and reduced side effects. Types of uncertainties
have to be identiﬁed, grouped, and quantiﬁed.
Methods: A detailed literature review was performed to identify uncertainty components and their rela-
tive importance to the combined overall uncertainty.
Results: Very few components (e.g., source strength and afterloader timer) are independent of clinical dis-
ease site and location of administered dose. While the inﬂuence of medium on dose calculation can be
substantial for low energy sources or non-deeply seated implants, the inﬂuence of medium is of minor
importance for high-energy sources in the pelvic region. The level of uncertainties due to target, organ,
applicator, and/or source movement in relation to the geometry assumed for treatment planning is highly
dependent on fractionation and the level of image guided adaptive treatment. Most studies to date report
the results in a manner that allows no direct reproduction and further comparison with other studies.
Often, no distinction is made between variations, uncertainties, and errors or mistakes. The literature
review facilitated the drafting of recommendations for uniform uncertainty reporting in clinical BT,
which are also provided. The recommended comprehensive uncertainty investigations are key to obtain
a general impression of uncertainties, and may help to identify elements of the brachytherapy treatment
process that need improvement in terms of diminishing their dosimetric uncertainties. It is recom-
mended to present data on the analyzed parameters (distance shifts, volume changes, source or applica-
tor position, etc.), and also their inﬂuence on absorbed dose for clinically-relevant dose parameters (e.g.,
target parameters such as D90 or OAR doses). Publications on brachytherapy should include a statement
of total dose uncertainty for the entire treatment course, taking into account the fractionation schedule
and level of image guidance for adaptation.
Conclusions: This report on brachytherapy clinical uncertainties represents a working project developed
by the Brachytherapy Physics Quality Assurances System (BRAPHYQS) subcommittee to the Physics Com-
mittee within GEC-ESTRO. Further, this report has been reviewed and approved by the American Associ-
ation of Physicists in Medicine.
 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology
110 (2014) 199–212Brachytherapy (BT) has evolved into a high-technology modal-
ity of radiotherapy incorporating 4D imaging and sophisticated
planning methods as standards of care. However, clinical BT uncer-
tainties have not been adequately addressed. Often, the technique
itself has been described without uncertainties in discussions
about dose-delivery accuracy or planning target volume (PTV)
and clinical target volume (CTV) margins [1]. It is apparent that
200 ESTRO/AAPM report: Clinical brachytherapy uncertainty analysisif the therapeutic radiation source is brought close to or into the
target volume, uncertainties in deﬁning location of the delivery de-
vice in relation to the regions of interest are small compared to
most external-beam radiotherapy (EBRT) methods. In BT, a source
is often placed within the target volume; there are very high doses
and dose gradients within this volume. However, the target vol-
ume can still be well covered with the prescribed dose.
BT is subject to uncertainties from imaging, treatment planning,
dose delivery, and anatomical variations. It is essential to identify
these uncertainties, their magnitude, and their impact on the over-
all uncertainty of dose delivery to the patient. This overall uncer-
tainty can be compared to that available for the most
sophisticated EBRT techniques, i.e., image-guided radiotherapy
(IGRT). Having this knowledge may provide correct dose assess-
ment for BT, dose effect modeling, and subsequently improved
clinical outcome when using better planning aims with dose and
volume constraints.
While the primary goals of estimating uncertainties in clinical
BT are to minimize therapy delivery variations and to improve pa-
tient outcomes such as disease-free survival and organs-at-risk
(OARs) toxicities, these outcomes cannot be estimated quantita-
tively in a direct manner for all situations. In most cases, the uncer-
tainties for the delivered physical dose per fraction can be chosen as
a surrogate for expected changes in biological response. However,
in cases where relationships with biologically weighted total dose
values are available, the overall uncertainty can be linked to these
total dose values by equi-effective dose with 2 Gy fractionation
using the linear quadratic model (EQD2) [2–4]. The purpose of this
report is to present aminimum standard for an uncertainty analysis
of the clinical practice of photon-emitting BT. The relationship with
absorbed dose is sought wherever possible. Identifying uncertain-
ties in the CTV delineation, including inter- and intra-observer var-
iability in target and OAR contouring, is not the goal of this report
and these uncertainties are only discussed for comparison.Methods and materials
Uncertainty deﬁnitions
The current standardized method for evaluating and expressing
measurement uncertainties is based on the Comité International
des Poids et Mésures (CIPM) report [5]. This method has been
developed further by the International Standards Organization
(ISO) in the Guide to the Expression of Uncertainty in Measure-
ment (GUM) as recently updated in 2010 [6] and by the U.S. Na-
tional Institute of Standards and Technology (NIST) Technical
Note 1297 [7]. This method categorizes uncertainties into either
Type A (statistical) or Type B (everything else) components.
Regarding the uncertainty of an observation, precision is the repro-
ducibility (Type A) of the observation while accuracy is the differ-
ence of the observation to the true value.
The magnitude and distribution of an individual uncertainty
component should be estimated. The established method for esti-
mating the overall uncertainty is to combine all uncertainty com-
ponents, expressed as relative standard uncertainties, in
quadrature. This may be visualized as Eq. (1) where si is the stan-
dard deviation of the mean of multiple measurements and is the
quadrature sum of all Type A uncertainties, and uj is the quadrature
sum of all Type B uncertainties.
V ¼ 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðs2i þ u2j Þ
q
ð1Þ
This approach assumes many degrees of freedom and non-cor-
related uncertainty components, which is generally the case for
clinical BT. In the GUM report, the overall uncertainty is expressed
as U. However, this nomenclature is not convenient for the ﬁeld ofBT since U is the recognized symbol for the units of air-kerma
strength. Consequently, the overall uncertainty in this report is ex-
pressed as V as recommended in the joint AAPM/GEC-ESTRO report
on BT dosimetric uncertainties (TG-138) [8]. Further, a 2 is present
before the square-root symbol to indicate a coverage factor of two
(k = 2) as recommended for clinical BT in the TG-138 report. Indi-
vidual uncertainty components should be estimated and expressed
with k = 1, with only the overall uncertainty expanded as k = 2 to-
ward estimating the uncertainty of an observation for a 95% conﬁ-
dence interval (assuming an approximately normal distribution).
The scope of this report is dosimetric evaluation for clinical pur-
poses, not for regulatory purposes or to identify medical events.Literature review
The ﬁrst step of this project was a joint brainstorming within
the GEC-ESTRO BRAPHYQS (BRAchytherapy PHYsics Quality assur-
ances System) experts to identify the different components of
uncertainty in BT. Working groups were appointed to collect data
for each uncertainty component for gynecological, breast, and
prostate BT. Data collection included literature review, internal
documents for commercial devices, and published quality assur-
ance (QA) guidelines or recommendations. Examples are provided
on the uncertainty type, value, and the reference. Based on this
information, a review of known and documented uncertainty com-
ponents and their magnitude is provided in an effort to deﬁne
overall uncertainties and, mainly, assess their relative importance.
The review facilitated the drafting of recommendations for uni-
form uncertainty reporting in clinical BT, which are also provided.Sources of uncertainty
General observations
During the literature review, there was a major difﬁculty
obtaining uniform information according to the currently deﬁned
uncertainty methodology of Section Uncertainty deﬁnitions. In
many cases, authors did not demarcate Type A from Type B uncer-
tainties. Uncertainties for technical afterloader parameters, appli-
cators, or organ movements were presented either in the
quantities of distances (e.g., mm) or in dose differences due to geo-
metrical shifts. Such dose differences were then reported as abso-
lute values (i.e., Gy) or as percentage dose differences (%). Absolute
dose values were reported for dose per fraction or the impact of the
uncertainties on the total dose. The percentage difference can be
related to dose per fraction, total dose from BT, or total dose from
EBRT plus BT (such as for combined therapies). Furthermore, all
these dose values could be presented as either physical dose or
EQD2 dose. Most uncertainties related to dose or volume parame-
ters were based on studies of institutional patient cohorts. This led
to differences in uncertainty reporting using, for example, mean or
median values and different ways to report variation (standard
deviation at k = 1, expanded uncertainties at k = 2, min/max, etc.).
In short, there is no uniform method in practice for reporting the
inﬂuence of uncertainties on BT dosimetric parameters. Conse-
quently, this report intends to provide a uniform reporting method.Source strength
Source strength is a basic parameter prevalent in all BT dose cal-
culation formalisms. It inﬂuences all levels of treatment planning,
from sophisticated 4D image-based plans to simple plans based
on time per source-strength unit taken from tables or dose atlases.
Consequently, calculations of BT absorbed dose uncertainties begin
with estimations of source-strength calibration uncertainties. Fol-
lowing AAPM Task Group 32 [9], ICRU 38 [10], and IAEA-1274
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source strength for photon-emitting sources in terms of air-kerma
strength, either SK or RAKR [12,13].
In the jargon of BT, the ﬁeld may be categorically divided into
low-energy (LE) and high-energy (HE) photon emitters, for which
50 keV serves as the boundary for the mean energy of the emitted
photon spectrum [14]; and also low-dose rate (LDR) and high-dose
rate (HDR) sources, deﬁned as resulting in absorbed dose rates
<2 Gy/h or >12 Gy/h, at the dose prescription level, respectively
[10]. BT sources may be used in either temporary or permanent im-
plants, an aspect that does not inﬂuence source-strength calibra-
tion uncertainties.
The most comprehensive report on uncertainties for BT
source strength calibration to date is the TG-138 report [8]. This
joint AAPM/ESTRO report covers the primary calibration stan-
dard, its link to the vendors providing a source-strength certiﬁ-
cate, and source calibrations performed at the departmental
level. It also examines the relative uncertainties in source-
strength calibrations for individual sources and estimates these
as 1.3% (k = 1) for LE and 1.5% (k = 1) for HE (see Tables 1 and
4 in the TG-138 report), except for LE-HDR. While this latter cat-
egory would include electronic BT sources or HDR 103Pd sources
where current source calibration methods are under develop-
ment and uncertainties involved are much larger than the afore-
mentioned values, the literature examined herein did not include
these source types.
Individual source strengths and their respective position within
an implant are not tracked in LE-LDR BT source implants. LE-LDR
sources are typically shipped by the manufacturer with source
strengths grouped in batches of ±2% to ±8% bin widths. Assuming
a rectangular distribution of source strength within these bins,
the calibration uncertainty increases (in quadrature) by r
2
ﬃﬃ
3
p or to
0.6% and 2.3%, respectively. In combination with the LE-LDR sin-
gle-source uncertainty of 1.3%, the overall uncertainty with these
bin widths increases to 1.4% and 2.6% when accounting for manu-
facturer source-batching practices as explained in the TG-138
report.Treatment planning
The current method of BT dose calculations is based on the
AAPM TG-43 dose calculation formalism [15,16]. Reference BT
dosimetry parameters are determined in the vicinity of a single
source that is centrally positioned in a spherical water phantom
of either 15 cm or 40 cm radius, for LE and HE sources, respectively
[17]. Treatment planning systems (TPS) incorporate BT dosimetry
parameters in a table-based approach where the approximate ef-
fect of dose falloff with diminishing solid angle is divided out as
the geometry function. While there are uncertainties in the deriva-
tion of each of the dosimetry parameters, it is their combined rela-
tionship upon TPS calculation of absorbed dose that is relevant to
clinical BT. Uncertainty in the calculation of absorbed dose to
water in water Dw,w will vary as a function of source type and loca-
tion of the point of interest P(r, h) in polar coordinates, and will in-
clude the source-strength calibration uncertainty described above.
At r = 1 cm along the source transverse-plane h = 90, the Dw,w
uncertainty is 3.8% and 2.6% for individual LE and HE sources,
respectively [8]. These values have been derived by propagation
of best practice uncertainties associated with source strength mea-
surements in the clinic (see preceding section), Monte Carlo (MC)
dose estimates, and TPS dataset interpolation (see Table 5 in the
TG-138 report). These uncertainties generally increase for smaller
r due to dynamic components and positioning uncertainties within
the source capsule and accuracy of the tabulated values at these
short distances. Uncertainties will also, more slowly, increase for
larger r due to the inﬂuence of material cross-sections as radiationpasses through thicker media with related uncertainties for dose
measurement or MC-method dose estimations.
With a conservative LE source-calibration uncertainty (k = 1) of
2.7% taken from an 8% wide batch, a LE dose calculation uncer-
tainty (k = 1) of 4.9% (differing from the 4.4% listed in Row 5 of Ta-
ble 5 in the TG-138 report due to batching) is combined with
additional uncertainties from subsequent clinically-oriented pro-
cedures as described in the following sections. Similarly, for the
HE dose calculation uncertainty (k = 1) of 3.4% (see Row 5 of Table 5
in the TG-138 report).
Another uncertainties aspect of brachytherapy is fractionated
treatments. Non-systematic uncertainties cause different delivered
doses per fraction. This results in differing overall uncertainties
depending on the number of fractions. Lowering the fraction dose
and increasing the number of fractions therefore results in less
uncertainty for the overall dose compared to one single observa-
tion in one fraction. For random uncertainties the number of frac-
tions n results in a factor related to 1/
ﬃﬃﬃ
n
p
for the overall
uncertainty. For such calculations, target and organ variations have
to be studied in detail for each individual treatment protocol in or-
der to distinguish the different components for the overall
uncertainty.Heterogeneity effects
Besides other sources of uncertainty associated with input
quantities to TG-43-based dose calculation algorithms, Type B
uncertainties are also involved due to the principles and assump-
tions of the TG-43 formalism. These stem mainly from heterogene-
ities, i.e., disregarding: (a) differences between tissue elemental
composition and density relative to water; (b) patient contour
and the position of the source(s) relative to the patient/air inter-
face; (c) high-Z materials present in the geometry including appli-
cators, shields, or permanent implants, and, to a lesser extent,
incomplete radiological physics approximations, i.e., charged parti-
cle disequilibrium, dose contribution by beta emissions, etc. A
comprehensive body of literature exists on the effect of heteroge-
neities for speciﬁc BT treatment sites/plans, determined using,
most commonly, Monte Carlo simulation. This literature has been
augmented in view of the advent of clinically feasible dose calcula-
tion algorithms capable of taking heterogeneities into account. An
extensive literature review is beyond the scope of this work and
interested readers are referred to reviews by Thomadsen et al., Riv-
ard et al., and Beaulieu et al. [18–20].
In the context of this work, existing literature serves as
acknowledgement that the magnitude of the offset that material
heterogeneities introduce relative to TG-43 dose calculations is
possibly important. According to the GUM [6], uncertainty compo-
nents arising from non-statistical effects (Type B) can be included
in a combined standard uncertainty evaluation in the form of stan-
dard uncertainties from established probability density functions
(PDFs) that are based on the current state of knowledge. However,
construction of these necessary PDFs is a formidable problem since
Type B uncertainty associated with material heterogeneities is
strongly dependent on position within the patient. Therefore, het-
erogeneities effects as reviewed in the following sections are com-
monly reported as the percentage changes in DVH parameters for
the PTV and OARs.
Low-energy
In permanent implants of LE sources used mainly for treatment
of prostate cancer, the dose delivered from any seed in an implant
is affected by the presence of the other seeds. This inter-seed atten-
uation (ISA) effect depends on radionuclide (i.e., photon energy),
source encapsulation, seed spacing, or equivalently seed density,
which in turn depends on prostate size and seed air-kerma
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with different spacing [21] or idealized implants [22] reported an
effect on conformity and homogeneity indices that becomes negli-
gible for 125I seeds spaced >0.5 cm apart. Subsequent studies of the
ISA effect were performed using MC simulations in clinical, CT-
based, pre- or post-implant geometries with results reported in
CTV and OAR DVH parameters employed for treatment plan evalu-
ation [23–26]. Assuming that seeds are coincident with the needle
insertion axis and without accounting for other effects such as ede-
ma or seed migration, results range between a negligible effect and
a CTV D90 overestimation of 1–5% depending on study design (pre-
or post-implant geometry), prostate volume, seed density, and
even seed model.
An important effect has also been reported due to the difference
of tissue and water in elemental composition and density
[23,25,27–29]. It should be noted that tissue composition informa-
tion is not currently available in routine clinical practice in contrast
to tissue density that can be readily obtained from CT imaging
data. In a recent comprehensive study, [29] Landry et al. reported,
inter alia, on the effect of tissue compositional uncertainties and
density on four clinical prostate 125I seed implants using three
prostate compositions taken from the literature, and four clinical
breast 103Pd seed implants using varying PTV adipose/gland ratio
and adipose/gland elemental composition. For prostate, it was con-
cluded that the effect of composition ranges from negligible to an
average D90 increase of 3.2% relative to water, while the use of den-
sities derived from CT data instead of unit density leads to a de-
crease of D90 values by 1–2%. For breast, replacing water by a
homogeneous tissue of a representative adipose/gland ratio is the
primary factor affecting dosimetric accuracy with the D90 found
to increase by 30% on average for a 70/30% adipose/gland ratio
due to the lower Zeff value resulting in lower attenuation. This is
followed by uncertainty in the composition of adipose and mam-
mary gland tissue, leading to a 10% variation in D90, and the use
of breast density from CT data, resulting in a 4% increase in D90
on average. In view of the above, the authors state that for breast
cases tissue composition effects overshadow the ISA effect re-
ported to correspond to a 3% decrease of D90 [30].
The most comprehensive study for prostate brachytherapy with
regard to the aim of the uncertainty project of this work is that of
Carrier et al. where MC dosimetry results are reported for a cohort
of 28 permanent implant patients [27]. The ISA effect was found to
result in a systematic D90 decrease with an average of 4.0 ± 0.4%
(k = 1) for a speciﬁc 125I seed model. The corresponding inﬂuence
on the OARs (urethra, rectum, bladder) was also a systematic de-
crease of all relevant DVH indices, subject however to increased
variability between patients. Taking tissue composition and den-
sity into account led to a systematic CTV D90 decrease of
2.6 ± 0.2% (k = 1) and a non-systematic effect to OARs.
The above results however were calculated using dose scoring
to medium as opposed to dose to water in medium used in the
study of Landry et al. [29]. It is also important to note that the dis-
tribution of the overall effect for the CTV D90 in the study of Carrier
et al. is neither rectangular nor Gaussian [27].
In conclusion, results on the ISA effect and tissue density for LE
sources might be considered conclusive while the quantiﬁcation of
tissue composition effects suffers from the lack of a routine clinical
method to obtain average data, local tissue heterogeneities (i.e.,
calciﬁcations) and non systematic effects for OARs.
High-energy
Temporary implants are almost exclusively performed using HE
HDR/PDR sources with remote afterloading technology so that ISA
effects are irrelevant. The increased relative importance of the
Compton scattering effect in dose deposition mitigates concern
for heterogeneity corrections other than that introduced by tissuedensity, tissue/air as well as tissue/lung interfaces, and the pres-
ence of shields or other high-Z materials. More important for HE
versus LE sources is the effect of the difference between scatter
conditions that ensue from the ﬁnite patient dimensions and the
spherical geometry used to generate TG-43 BT dosimetry parame-
ters [31].
In gynecological (GYN) and rectal treatments, the effect of
neglecting the attenuation and scatter reduction due to the use
of high-Z materials has been examined in the literature [32–37].
Dose perturbation by partial shielding varies substantially with
shield material, shape and size well as location. The most impor-
tant offset of the dose distribution occurs in the shielded region,
but its magnitude is both distance- and position-dependent and
is consequently not constant even for a particular applicator. Per-
haps most important, diminishment of scattered radiation from
the shielded portion of the irradiated volume can noticeably re-
duce dose in the unshielded target volume. Recent retrospective
assessments of HDR 192Ir tandem-and-ovoid treatments using a
dose calculation algorithm capable of accounting for material het-
erogeneities have reported a minimal impact on clinical dose
parameters [38,39]. Greater differences are only reported in case
of radiographic contrast used for packing and mainly for the rec-
tum dose.
In 192Ir breast treatments, patient scatter conditions led to an
average TPS dose overestimation of 14% at points close to the tis-
sue/air interface using experimental methods [40]. A subsequent
study [41] using MC simulation in a mathematical, patient-equiv-
alent geometry for a multi-catheter implant showed that percent-
age isodose lines greater than 60% of D90 were not affected by the
ﬁnite breast dimensions or the presence of the lung. However, TPS
based on the TG-43 formalism overestimated lung dose and lower
isodose lines at points lying both close to the breast or lung surface
and away from the implant. Skin dose overestimation was 5% in
the central breast region and within 10% at all other points. This
TPS dose overestimation was greater for 169Yb than 192Ir, reaching
15–30% [42]. A direct comparison of TG-43 based dose calculations
to MC simulations in the CT-based geometries of 18 multi-catheter
breast patients taking into account four tissue types was included
in a study introducing an analytical scatter correction technique
[43]. Average results, reported in terms of dose-volume statistics
for the PTV, skin, lung, and heart veriﬁed the magnitude of the
TG-43 dose overestimation (i.e., 2.6 ± 0.6% for PTV D90, 4.7 ± 1.2%,
5.3 ± 0.9%, 2.1 ± 3.7% for skin, lung, and heart D0:1cm3 , respectively).
Besides multi-catheter implants for HDR 192Ir breast BT, heter-
ogeneities and tissue/material interface effects also affect the
dosimetry of treatments using dedicated partial breast irradiation
applicators due to the presence of iodine-containing radiographic
contrast medium or air, the ﬁnite breast dimensions, and the low
density of the lung that are not considered by TG-43 based TPS
[44–49]. Comparison of TPS and MC calculations in breast/lung
phantoms showed that the TPS overestimates prescription dose
by 4–10%, depending on the concentration of the contrast medium
and source direction in a Mammosite applicator, owing mainly to
scatter conditions rather than attenuation in the contrast medium
which contributed 1.0–4.8% for iohexol (Omnipaque™) concentra-
tions 5–15% by volume in a 45 mm diameter balloon. This overes-
timation can be addressed for 192Ir with simple analytical methods,
but not for 169Yb due to photon spectrum hardening. A dosimetric
effect ranging from 3% to 9% has also been reported due to the air
in the SAVI applicator [49].Dose delivery
Positional accuracy
Dose delivery accuracy depends on the consistency of the pa-
tient and delivery device (sources) geometry between treatment
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ple of temporary implants, geometry includes the position of the
source inside the applicator and the applicator position inside
the patient in relation to target and OAR structures. The uncertain-
ties depend on the applicator type, applicator design, and the clin-
ical disease site.
Systematic effects of afterloader accuracy can be veriﬁed at
commissioning and constancy checks. It is possible to calibrate
and eliminate systematic shifts resulting only from the afterloader.
However, the constancy (precision) of source positioning during
treatment remains to be documented. According to manufacturer
speciﬁcations, a source precision of ±1 mm can be achieved. Source
positioning for HDR and PDR 192Ir afterloaders has been evaluated
based on measurements performed in 33 institutions in the Neth-
erlands and Belgium [50]. The standard deviation for source-posi-
tioning offset for 16 HDR 192Ir afterloaders and 11 PDR 192Ir
afterloaders was ±1.0 mm and ±1.1 mm, respectively. Recently,
Manikandan et al. reported dwell position uncertainties for a
new generation afterloader using a detector array also showing a
standard deviation (k = 1) of 1.0 mm [51]. All these uncertainties
are for straight applicators and transfer tubes. The source path is
deﬁned as the set of subsequent source positions that can be
reached inside the applicator. Inside a curved applicator, the BT
source attached to a drive cable is pushed toward the outer wall
of the applicator [52], which leads to a deviation of the source path
from the expected path (simulated by the CT, X-ray, or MRI mark-
ers) and the source position compared to source movement in a
straight applicator. This results in discrepancies between expected
and true source positions, which depend on applicator curvature.
Discrepancies of up to 2.5–4.5 mm have been measured in the ring
applicator [53–55], and up to 5.5 mm in a 33 mm diameter curved
plastic applicator [56]. Type B uncertainties can be substantially
decreased by appropriate localization and deﬁnition of the source
path during commissioning and/or treatment planning [57,58]. In
most cases, the diameter of the assumed circular source path that
best ﬁts to the real positions will be different than the nominal
diameters of the source path. The tension effect of the cable can
even result in different subsequent source positions than the pro-
gramed step size or even no change in source position for pro-
gramed steps of 1–2 mm in some afterloaders [59]. Fortunately,
it is possible to minimize many of these uncertainties by digitizing
the real source path during applicator commissioning and using
this path for treatment planning. This task will be facilitated with
reconstruction tools based on recently available applicator libraries
[57].
Another source of uncertainties is the source orientation inside
the applicator. For straight applicators, orientation is closely
aligned to the source path axis. However, the orientation can be
different and not tangential to the source path for curved applica-
tors, especially when the source channel is large compared to the
source. This effect will inﬂuence the dose distribution. A similar ef-
fect, but with a smaller impact on clinical dosimetry, has been re-
ported for unknown orientations of loose seeds inside the prostate
[24,60]. In general, the dosimetric consequences of source mis-
placements are similar to applicator misplacements. In both situa-
tions, the physical source position is different from that of the
treatment plan position. The impact is speciﬁc to clinical disease
site and is presented in the next sections.
Temporal accuracy
Dwell time delivery by the afterloaders has been veriﬁed using
a specially developed QA tool with a temporal accuracy of 1 ms
[61]. Evaluating the accuracy and precision of an HDR 192Ir BT
afterloader, the authors found that the bias in dwell time can ex-
ceed 60 ms and the dwell time associated with the ﬁrst dwell posi-
tion unexpectedly differed by 30 ms. Transit dose, tissueirradiation during source movement, is not taken into account in
treatment planning. Measurements in a phantom with the source
positioned 5.0 cm from the detector and a dwell time range of 0–
120 s for Nucletron HDR and PDR 192Ir afterloaders [50], showed
that the transit dose varied from 0.004 Gy for a 0.04 Gy m2/h
HDR source to 0.0004 Gy for a 0.004 Gy m2/h PDR source. Relative
to the planned doses of 0.75 Gy and 0.40 Gy for HDR and PDR after-
loaders, respectively, the maximum contribution of the transit
dose to the measured dose was 0.5% for HDR and 0.1% for PDR
afterloaders. Additional measurements conﬁrmed that the manu-
facturers of the afterloaders compensate for the effects of inter-
dwell transit dose by reducing the actual dwell time of the
source [62]. The dwell time of the source at each dwell position
was reduced by the time taken for the source during transit to
compensate for the transit dose. For example, for a source step size
of 5 mm and a planned source dwell time of 2 s, the measured
average dwell time was 1.93 ± 0.01 s with an average transit dose
compensation time of 0.07 ± 0.01 s. Uncertainties due to transit
dose could also be minimized by taking them into account during
treatment planning [63].
Another potential issue is the ‘‘rounding error’’ introduced
when exporting the treatment plan to the afterloader control unit
or from the control unit to the afterloader itself. The largest round-
ing effect can occur when the dose distribution is not optimized
and all dwell weights are set to unity, depending on the dwell time
values. When the dose distribution is optimized, all dwell weights
are different and the rounding-off errors more or less average out.
In an optimized dose distribution, temporal rounding-off for a pre-
scription dose of 5 Gy dose is usually <1.0%.Imaging
Imaging allows registration of the dose distribution to the pa-
tient anatomy. This process is mostly used for aligning the applica-
tor and source path or the outer applicator surface and patient
anatomy so 3D dose distributions can be matched to points and
volumes reconstructed from radiographs (2 orthogonal ﬁlms, vari-
able angle or other techniques), CT, MRI, and/or ultrasound (US)
images. For the case of 3D imaging (CT, MRI, US) volumes are
reconstructed most often from 2D contours on sectional slices or
volumetric contouring. For DVH calculations the dose distribution
has to be calculated within these structures. Computational limita-
tions and assumptions due to the ﬁnite slice thickness result in
several sources of uncertainties. Depending on the shape and posi-
tion of structures, standard deviations of 1–5% in phantom conﬁg-
urations have been reported for cumulative DVH parameters
related to 2 cm3 volumes (D2cm3 ) when using different commercial
TPS [64]. However, large deviations for D100 have been reported for
target structures, up to 5–20%, depending on algorithm version and
sampling points. D100 is typically linked to a single voxel within the
structure. As proposed for EBRT, D98 (termed ‘‘the near minimum
dose’’) may be a superior metric [65–67].
For images with tandem/ring and tandem/ovoid applicators in
place, Aubry et al. reported mean absolute imaging distortions of
0.4 mm, 0.8 mm, and 0.8 mm or less for CBCT, MR-T1, and MR-T2
images, respectively [68]. For fusion of magnetic resonance spec-
troscopy images with CT or US studies using a mapping algorithm,
Mizowaki and colleagues report 3D-positional errors of
2.2 ± 1.2 mm (k = 1) [69]. Kolkman-Deurloo and colleagues pre-
sented reconstruction uncertainties using an Integrated-Brachy-
therapy-Unit (IBU) for head-and-neck cases [70]. For two
patients, the reported deviations in total irradiation time were
1.1% and 0.5% without distortion correction of the ﬂuoroscopic
images and 0.3% and 0.0% with distortion correction. In particular
for head and neck cases, the implanted plastic catheters have loop
geometry. This can result in source positioning uncertainty inside
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positioning uncertainties for 360 loops depend on the loop diam-
eter and might differ among afterloading devices [56]. Offsets of
several millimeters were found. Nevertheless, the largest offsets
were found for catheter loops having radii less than the system
speciﬁcations. Moreover, 360 loops are not used in typical patient
cases. The impact of reconstruction uncertainties on dose to struc-
tures is dependent on clinical disease site. These effects are dis-
cussed in the following sections for GYN, breast, and prostate.
Uncertainties at the patient level
Generalized uncertainties for gynecological malignancies
With CT-based reconstruction, intracavitary applicator registra-
tion is usually excellent (within 1 mm). Dose variations are small
(<4%, k = 1) between different CT reconstruction methods at clini-
cally-relevant dose points [53]. Even with MRI-based reconstruc-
tion, the variations between different reconstruction methods as
well as inter-observer variations are limited to 0.5–1.0 mm
(k = 1) [71]. The consequence of reconstruction offsets depends
on the offset direction and the examined organ [72]. Rectum and
bladder are the organs most sensitive to these uncertainties with
D2cm3 changes of 5 ± 1%/mm for applicator reconstruction offsets
in the anterio–posterior direction where 90% of the patients have
changes <6%/mm. For other directions and for the HR CTV (D90,
D100) and sigmoid (D2cm3 ), average changes are <4%/mm although
individual patients show reconstruction offsets up to 5%/mm. A
systematic rotation of the source path by 2.5 mm, i.e., one source
dwell step size, may lead to a deviation of the rectum D2cm3 of up
to 5%, and up to 2% for HR CTV D90 [58]. Berger et al. [52] as well
as Wills et al. [73] found deviations of 5–10% (one standard devia-
tion) for HR CTV D90 and OAR D2cm3 for different reconstruction
methods and observers, respectively. In a series with repeated
applicator reconstruction, Hellebust and colleagues observed a rel-
ative standard deviation of 5.6% for rectum D2cm3 [74]. By using the
results from Tanderup and colleagues, the deviations found in
these studies [52,73,74] could be explained by an applicator shift
of approximately 1–2 mm in the longitudinal direction [72]. This
is in accordance with the results from Haack et al. [71]. Kubicky
et al., who estimated minimum and maximum applicator shifts
to be 1.625 mm and 3.25 mm, respectively. They used results from
a previous study to translate these shifts into an average dose
uncertainty of 1–2% [75], much smaller than the uncertainties
found by Tanderup et al. and Hellebust et al. These discrepancies
are explained by the fact that the estimation by Kubicky et al.
was based on random shifts of 16–18 needles in a prostate implant,
not well representing the dose distribution of a GYN intracavitary
implant.
Applicator stability and organ variations, fractionated treatments
Since the BT dose gradient is steep, small changes in the relative
position of a structure and applicator could lead to large changes in
the DVH parameters. Applicator displacements relative to impor-
tant anatomical structures (target volumes and OARs) can occur
between applicator insertion and treatment delivery or during
treatment delivery itself, especially when using LDR/PDR treat-
ments subtending many hours. The type of applicator, ﬁxation
method, and vaginal packing are crucial factors determining appli-
cator stability. Stable applicator geometry with movements rela-
tive to rectum diodes below 1.2 ± 0.7 mm (k = 1) in all directions
has been reported during PDR 192Ir BT delivery with tandem-ring
applicators [76].
De Leeuw et al. analyzed applicator movements relative to bony
anatomy during PDR delivery and found geometrical shifts as large
as 6 ± 7 mm (k = 1) in the posterior direction [4]. Several studieshave previously reported such movements related to the bony
structures. However, such analyses neglect that the target and or-
gans may also move relative to the pelvic bones. If an intracavitary
applicator is ﬁxed to the cervix by packing, applicator movement
will follow movement of the cervix and related target volumes. Re-
cent studies are based on 3D imaging in order to assess geometric
changes between the applicator and the target volumes or the
OARs. Such changes can happen during an implant, in between
two implants, or between imaging and dose delivery. The clinical
relevance of the geometrical shifts is found by analyzing the
change in DVH parameters for the structure of interest.
De Leeuw et al. analyzed the dosimetrical consequences of
applicator displacement seen during a PDR 192Ir BT fraction and
found occasional applicator displacements resulting in consider-
able target dose changes for individual outliers [4]. Mean changes
after 22 h in bladder and rectal doses for 18 applications were
4 ± 12% and 4 ± 23%, respectively [4]. The changes for CTV were
on average 1 ± 9%. Dose for the whole treatment, including two
PDR 192Ir BT fractions, varied by only 0.3 ± 2.8 Gy. While move-
ments relative to the bones showed some inﬂuence on the OAR
dose variations, no such relation was detected for the CTV.
If one BT plan is applied for several fractions, interfraction vari-
ations will increase dose uncertainties. For EBRT, the treatment is
usually delivered with more than ten fractions and interfraction
variation is often quantiﬁed in terms of standard deviations.
Ascribing standard deviations to intrafraction motion is not suit-
able for a BT schedule with 63 treatment fractions. Hellebust
and colleagues used this approach for gynecological BT and dem-
onstrated that the average relative standard deviations for 13 ser-
ies of 3–6 fractions were 15% and 17.5% for D2cm3 for the rectum
and bladder, respectively [74]. They did not examine the total
treatment course at the individual patient level. However, such
analysis was performed by Kirisits et al. and Beriwal et al. [3,77].
Kirisits et al. compared individual MRI-based 3D treatment plan-
ning for each of four fractions with the use of only one MRI treat-
ment plan for 14 patients. They found signiﬁcant mean differences
relative to the BT dose (not including EBRT) of 14%, 9%, 22%, and
28% for HR-CTV D90, bladder D2cm3 , rectum D2cm3 , and sigmoid
D2cm3 , respectively. On an individual patient level, much larger dif-
ferences were seen. For example, the single-plan method would
have resulted in an increased sigmoid dose of more than 24% for
seven patients. However, this analysis was based on patients with
BT applications throughout the EBRT course, resulting in substan-
tial target volume shrinkage across the BT applications. Mohamed
et al. performed the same kind of analysis in a treatment schedule
with intracavitary PDR 192Ir BT starting in the last week of EBRT or
following EBRT after most tumor shrinkage had occurred [78].
They found no signiﬁcant differences between the single-plan
method and repeated planning for the majority of parameters.
However, there were considerable individual variations of 1 Gy to
3 Gy for total HR CTV D90 and OAR D2cm3 (EQD2) that indicates that
reporting of mean values is not sufﬁcient in plan comparison. Beri-
wal et al. performed a similar analysis [77], but compared treat-
ment planning based on only MR acquisition to treatment
planning based on MR for the ﬁrst fraction and then CT for the con-
secutive fractions. Analyzing the average DVH parameters, they did
not ﬁnd signiﬁcant differences between these two methods. The
range of differences was not presented and it is therefore difﬁcult
to comment on individual patient variations.
Lang et al. investigated the consequences of using one MR
acquisition per insertion (delivering two fractions) instead of per-
forming MR imaging prior to each fraction [79]. They found that
systematic differences in the mean total EQD2 dose including EBRT
were small (usually below 1%) for target and OAR dose parameters.
However, the statistical uncertainties (k = 1) reached 3% for HR CTV
D90, and up to 6% for OAR D2cm3 . In total dose, this corresponds to
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nitude varies with small, medium, and large variations for the tar-
get, rectum, and both the bladder and sigmoid, respectively.
However, care is required to draw general conclusions from these
data. This study used a speciﬁc treatment schedule, did not have a
ﬁxed protocol for bladder ﬁlling, and employed a speciﬁc method
for applicator placement and ﬁxation by packing. Furthermore,
while the uncertainties for a single fraction applying a treatment
plan based on a single MRI for the ﬁrst fraction are 12% for D90
and 23% for D2cm3 for the highly-mobile sigmoid, this is compen-
sated by summation of several BT fractions and addition of the
EBRT dose.
In a study comparing 10 CT- and MRI-contoured cervical pa-
tients Viswanathan et al. [80] found that CT-based delineation of
the OAR is sufﬁcient. On the other hand they reported CT-based tu-
mor contours are overestimating the tumor width. In particular a
statistically signiﬁcant difference for the MRI-based D90 with
5.6 Gy. vs. 4.6 Gy for the CT-based D90 of the HR CTV was found.
Nesvacil et al. [81] compared interfraction variations for 123
patients from different centers, who observed effects of OAR mo-
tions occurring during BT on the D2cm3 (physical dose) using ﬁxed
BT plans and two image sets taken at different timepoints (inter-
vals ranging from 5 h to 22 days). No systematic correlation be-
tween the relative change of D2cm3 and the time interval between
observations was found. For OAR, standard deviations (k = 1) for
differences between two single situations (either applications or
fractions) was above 20% and around 13% for HR CTV D90. However,
the overall uncertainty is reduced similar to the single center expe-
rience described above for HDR fractionated treatment and multi-
ple PDR pulses.
Mikami et al. investigated applicator displacements during
interstitial GYN BT using cylinders and/or perineal templates.
Due to the long distance of the needles in tissue, there is a displace-
ment of the needle tip, mainly to the caudal direction. [82]. While
the mean displacement is only 1 mm within 21 h, outliers of up to
12 mm were observed.
Some of the studies mentioned above found large interfraction
variations while others did not. The analyses performed and the
data presentation deviate considerably among studies; this makes
comparisons difﬁcult. However, one common ﬁnding is seen –
some large deviations are observed for individual patients, even
if the mean values do not exhibit large variations. Another impor-
tant observation is that all the analyses are based on new contour-
ing and applicator reconstruction in a second image set. In
particular, contouring uncertainty can affect the DVH parameters
and consequently the study results and conclusions.
Calculation of cumulative OAR doses from succeeding BT frac-
tions relies currently on addition of D2cm3 values for subsequent
BT fractions and not on a summation of dose values in individual
voxels. This approximation can lead to OAR dose overestimation
when different organ parts are exposed to a high dose in different
fractions. For the bladder, the effect on D2cm3 has been shown to be
minor with a median overestimation of 1.5%, whereas the
D0:1cm3may be overestimated by 11% (EQD2) [83].The same conclu-
sion regarding a ‘‘worst case assumption’’ is expected to apply for
the rectum due to limited organ mobility, whereas dose overesti-
mation to the sigmoid might be clinically relevant, although this
has not been rigorously assessed.
Finally, the total dose for most gynecological treatments results
from a combination of BT and EBRT. The current standard is to take
the EBRT dose that is representative of the homogenous dose pla-
teau, and add it to the BT fractions. This dose is usually the pre-
scribed dose to the ICRU 50 point or D50 for IMRT. Van de Kamer
et al. investigated the uncertainties that are introduced by such a
direct adding of the parameter values [84]. Without any additional
EBRT boost, additively accurate results can be expected. However,any form of boost that is not taken into account by proper voxel-
wise dose summation or sufﬁcient surrogate methods can underes-
timate HR-CTV D90 by up to 10 ± 6.2%, especially lymph node
boosts, and even more pronounced for the parametrium. For para-
metrial boosts, there are signiﬁcant uncertainties related to evalu-
ation of total dose to the target and OARs. Fenkell et al. [85]
critically evaluated the assumption that the midline block fully
protects OARs (bladder, rectum, and sigmoid) while delivering full
parametrial boost dose to target regions not covered by intracavi-
tary BT dose. However, they concluded that this assumption was
not valid. The parametrial boost contributed 30–40% of the pre-
scribed parametrial boost dose to D2cm3 in OARs while only improv-
ing the D90 of HR CTV and IR CTV by 50–70% of the prescribed
parametrial boost dose.Generalized uncertainties for breast malignancies
Modern multi-catheter breast techniques are normally accom-
plished using an HDR or PDR 192Ir afterloading unit. After general
or local anesthesia, stainless steel needles are placed free-hand or
template-based into the breast tissue with inter-catheter spacing
of about 1.0–2.0 cm in two to three rows. These needles can be re-
placed by ﬂexible plastic tubes and secured with special buttons at
the patient’s skin surface. Catheter reconstruction can be per-
formed either by orthogonal ﬁlms or in a modern approach using
CT as the basis for the 3D treatment planning process. In many
cases, the target region (i.e., the lumpectomy cavity) is marked
by surgical clips to identify the target volume.
In a combined phantom/patient study, Hensley et al. [86] re-
ported a CT-based catheter reconstruction uncertainty of 1.1 mm
to 2.8 mm. Further they found that larger uncertainties can occur
due to patient movements while the CT scanning is in process.
These ﬁndings are related to a relatively slow CT scanner, so that
breathing artifacts and partial volume effects are included in the
catheter reconstruction. Nevertheless, Aristei et al. [87], Cuttino
et al. [88], and Das et al. [89] showed the beneﬁts of 3D-CT based
catheter reconstruction over 2D-techniques. A cohort of 50 consec-
utive patients underwent CT-based treatment planning and dosi-
metric results were compared against conventional orthogonal
ﬁlm dosimetry using the Manchester system. CT-based treatment
planning showed excellent visualization of the lumpectomy cavity,
normal structures and better target volume delineation and cover-
age were achieved. Dwell times of the CT-based technique were in
±7% agreement to those of conventional plans. Cuttino et al. ob-
served PTV D90 increased from 89% to 95% (p = 0.007) when chang-
ing from a 2D technique to a CT-guided technique. Moreover the
dose homogeneity index showed an increase from 0.77 to 0.82
after changing to the 3D technique (p < 0.005). On the other hand,
Kolkmann-Deurloo et al. presented accurate results in a study per-
forming reconstructions by using an IBU [70], with average recon-
struction offsets of 0.6 mm without distortions correction and
0.2 mm with correction for 25 cm images from a radiograph-based
device.
In the book by Wazer and colleagues [90], Das and Thomadsen
mentioned that catheters can shift in the breast, and there is no
easy way to adjust the relative source positions to the target. Mar-
gins in the direction of the catheters must include this uncertainty.
A 2 cm CTV-to-PTV expansion is suggested for the overall
uncertainty.
Contouring uncertainties for breast BT were studied in the work
of Landis et al. [91]. The lumpectomy cavities of 33 patients were
evaluated. The cavity, including a 1.5 cm margin, was deﬁned as
target volume in a CT dataset by four experienced physicians.
The mean PTV was 215 cm3, with volumetric variations ranging
from 7% to 42% per patient depending on the visibility of the lump-
ectomy cavity. In a similar study, Petersen et al. presented the
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[92]. The CI is the ratio of overlapping volume and the encompass-
ing delineated volume – in this case for the target volume. A mean
CI value of 0.61 (0.27–0.84 range) was observed.
Interfraction variations were investigated by Kim et al. using
the MammoSite balloon applicator [93]. In a study of 19 patients
with 10 fractions and CT imaging obtained before each fraction,
they found that interfraction variations were patient speciﬁc and
not clinically relevant for targets and OARs, but maximum varia-
tions could be clinically meaningful. The average trapped air gap
volume was reduced from 3.7 cm3 following implant to 0.8 cm3
at time of ﬁrst treatment fraction. MC calculations and phantom
investigations in MammoSite balloons were performed by Kirk
et al. to evaluate dose perturbations by contrast media [45]. They
found heterogeneity correction factors of 0.99 and 0.98 for 2 cm
and 3 cm balloon diameters, respectively, using 6% by volume of
contrast solution.
Plans of 15 MammoSite patients were analyzed by Todor et al.
[94]. They reported that respiratory motion, tip location mismatch,
and daily source position variation are the main factors for dose
delivery uncertainty. Due to respiratory motion, balloon volume
can be underestimated by 8% and 16% for CT and CBCT, respec-
tively. The D95 coverage decreased when the applicator tip was
not delineated properly. When using small balloons (about
35 cm3) a 3 mm uncertainty resulted in a D95 coverage decrease
from 96.3% to 92.6%. For a large balloon (about 99 cm3) D95 cover-
age decreased from 98.7% to 79.3%. However, it is not obvious why
the variations with the large balloon are larger than with a small
one. These are the only published data on this type of uncertainty.
With a daily source position variation of 1 mm, D95 coverage de-
creased from 98.7% to 88.2% over the course of 10 fractions for
the 99 cm3 balloon.Generalized uncertainties for prostate malignancies
Besides contouring uncertainties, source positioning relative to
the target and OARs is the main source of uncertainty for prostate
dosimetry. For permanent seed implants, the target volume
changes substantially during the time of relevant dose delivery.
Prostate swelling compared to day-0 volume varies between 30%
and 90%, and then edema resolves exponentially with a mean
half-life of 9.3 days [95,96]. Post-implant edema is usually not con-
sidered in the pre-procedural plan dose calculations. However,
edema may have a considerable impact on the delivered dose.
The impact of edema on prostate dosimetry was modeled by Yue
et al. [97]. They found that for a set of assumed edema parameters
(50% volume increase and 10 day volumetric half-life), static 125I or
103Pd pre-procedural plans overestimate total dose by about 5%
and 12%, respectively.
The variation of permanent prostate BT dosimetry as a function
of seed localization uncertainty was investigated for 125I implants
by applying Gaussian noise with standard deviations ranging from
0.5 mm to 10 mm to the seed coordinates of post-procedural plan
datasets [98]. The results demonstrated that <5% deviation of pros-
tate D90 can be expected when seed localization uncertainty is
2 mm, whereas a seed localization uncertainty of 10 mm yielded
an average D90 decrease of 33 Gy. Because of its lower energy
and higher dose gradient, the magnitude of seed localization
uncertainty is higher for 103Pd implants, and the opposite is true
for 131Cs implants due to their higher energy and lower dose
gradient.
In a multi-institutional study by the GEC-ESTRO BRAPHYQS
group, Siebert et al. analyzed the impact of CT parameters on seed
localization variations [99]. Seed reconstruction accuracy was not
dependent on scanned ﬁeld-of-view, tube current, tube peak
voltage, and scan type (axial or spiral). They found CT seedreconstruction accuracy decreases in the longitudinal direction
when slice thickness or table index (pertinent pitch for helical
scans) >4 mm. For example, using a 2 mm axial slice thickness
and table index had a 0.2 mm uncertainty whereas a 5 mm slice
thickness and table index had a 0.7 mm uncertainty. Moreover,
the quality of seed reconstruction can be dependent on seed model
when using seed-detection software. In a phantom test pattern
consisting of 9 dummy sources, 0–3 mismatches occurred [99]. A
similar phantom study was published by DeBrabandere et al., but
included MRI imaging [100]. They inserted 60 dummy seeds into
a newly designed gel-based phantom and performed CT and MRI
scans. Seed reconstruction uncertainties for 3 mm, 4 mm, and
5 mm thick slices were smaller for CT than MRI (1.5 T) datasets,
being 0.9 ± 0.6 mm, 0.9 ± 0.6 mm, and 2.1 ± 0.8 mm for CT and
2.1 ± 1.4 mm, 1.6 ± 1.2 mm, and 1.9 ± 0.9 mm for MRI, respectively.
A further study by the GEC-ESTRO BRAPHYQS group compared
uncertainties introduced by contouring, seed reconstruction and
image fusion for three patients [101]. Interobserver variation for
these three aspects was investigated for post-procedural planning
dosimetry using CT alone, T1 and T2 weighted (fused), and CT and
T2 weighted (fused) MRI datasets. The largest standard deviations
were found for contouring and fusion. The impact on D90 was
highly technique dependent: for contouring, the standard devia-
tions (k = 1) were 23%, 18%, and 17% for CT, T1 + T2, and CT + T2,
respectively. The D90 uncertainties for seed localization were smal-
ler, 2%, 7%, and 2% for CT, T1 + T2, and CT + T2, respectively. Fusion
uncertainties in D90 were 6% and 16% for T1 + T2 and CT + T2,
respectively.
In an extensive study, Lindsay et al. demonstrated that contour-
ing uncertainties and seed localization uncertainties have a large
impact on the predicted radiobiological outcome for LDR 125I pros-
tate seed patients [102]. They observed that the largest impact on
dosimetry was found to be seed localization uncertainties (6 mm)
resulting in changes of the D90 of the prostate of more than 10%.
The mentioned maximum 6mm uncertainty of seed localization
is, compared to other studies, very conservative. Nevertheless it
must be pointed out that this was a simulation study, i.e. the uncer-
tainties are of a theoretical nature and do not account for uncer-
tainties in radiobiological parameters.
For HDR 192Ir BT, substantial changes of the implanted needles
relative to the target geometry have been reported between indi-
vidual fractions when a single implant and CT-based planning is
used. A classic report on this topic demonstrated the shift of the
interstitial needle tips in the direction of the prostate apex [103].
Without any corrective measures, the mean prostate D90 dropped
from 96% to 64%. This effect was reported by several other groups,
also with substantial OAR dose uncertainties [104–107]. Either a
cranial PTV margin is needed and/or imaging should be performed
for each fraction followed by correction of the dwell time distribu-
tion or the needle positions. Another solution is needle design
improvement for better needle ﬁxation to the target. Instead of
afﬁxing needles to a template outside the body, needle tip ﬁxation
inside the target volume is a promising alternative. The mean abso-
lute displacement for such self-anchoring needles during a 3-day
PDR 192Ir, prostate BT treatment was 1.2 mm [108]. However,
mean absolute differences are not directly comparable to the sys-
tematic mean difference and the distributed standard deviation.
Different from the experience with CT-based dosimetry, a 3D
US-based treatment protocol was tested by performing imaging
for the treatment plan plus two 3D US scans close in time to dose
delivery [109]. Although a systematic change was observed, the
average needle displacement was 1 mm. These geometric changes
result in only 1.6% D90 reductions. However, some parameters were
inﬂuenced by up to 5% in individual patients. A possible conclusion
is to limit applicator displacement and other geometric variations
to 61 mm. Not only is displacement of the implanted applicator of
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the needle tips). In phantom investigations, Siebert et al. showed
that US-based needle tip localization in the sagittal view was accu-
rate within 1 mm, yet subject to inter- and intraobserver variations
in manual needle tip detection [110]. Further, lower US system
gain settings (15 dB compared to 15 dB) reduced intraobserver
variations. Peikari et al. found needle localization variations of
0.5–4 mm, depending on needle position with respect to the US
ﬁelds and settings of gain and power [111]. The inﬂuence of geo-
metric uncertainties on dosimetry was evaluated in a model-based
simulation [112]. Source positioning along the catheter and cathe-
ter reconstruction uncertainties of 1.5 mm and 1.0 mm, respec-
tively, led to <2% dose uncertainty for dose volume parameters
related to lower doses than 200% of the prescribed dose and reach-
ing up to 5% dose uncertainty at locations within a couple millime-
ters of the catheters. These uncertainties inﬂuenced PTV dose and
urethra DVH results by <1%. Catheter-reconstruction uncertainties
of 2 mm caused dose uncertainties of 2–9% for locations inside the
150% isodose contour.Example uncertainty estimates
The three disease sites discussed above are examined in the fol-
lowing examples of dosimetric uncertainty estimation. Uncertainty
components are ordered in a quasi-chronological fashion. These
dosimetric uncertainties correspond to k = 1 typical values that
can be achieved with current technology. If not otherwise stated
AAPM TG-43 formalism was used for dose calculation. Researchers
should report their own ﬁndings and identify means of minimizing
the largest prevalent dosimetric uncertainties. The inter- and intra-
fraction changes between imaging and dose delivery need special
attention to quantify resultant dosimetric uncertainties – this is a
ripe area for research. In common to these uncertainties is the bias
with inter- and intra-observer variations in contouring. Contouring
uncertainties inﬂuence both inter- and intra-observer variations.
Any study delineating an organ or a CTV on two image sets in-
cludes these variations in the overall results. Interobserver varia-
tions have been reported to inﬂuence D90 or D2cm3 values by
several percent [113] as is the case with intraobserver variations
on target volume dose parameters [114]. Assuming normal distri-
butions for the interfraction and intraobserver (i.e., contouring)
uncertainties, with no interrelationship, the square of the total
uncertainty will correspond to the sum of the squares of the inter-
fraction and contouring uncertainties. As one cannot directly as-
sess the interfraction uncertainty, it may be derived from the
square root of the difference between the squares of the total
and contouring uncertainties. Analysis of this bias in any clinical
study (including contouring) has not been reported so far for BT.
Therefore, the given values for interfraction effects could slightly
overestimate the real uncertainties given their inclusion of the
intraobserver component [115]. The total dosimetric uncertainty
is also given with k = 1. The major contribution follows from con-
touring and intra/interfraction variations. For these kinds of uncer-
tainties, the normal distribution is not true for large values.
Anatomy limits the possible situations, i.e., during fractionated
treatment an organ usually cannot get closer to the implant that
is in the direct vicinity of the target volume.
HDR 192Ir GYN vaginal brachytherapy
In this example, Table 1, the relative dosimetric uncertainty is
assessed at a point on the transverse plane on the surface (or at
5 mm depth) of a 30 mm diameter vaginal cylinder BT applicator
(e.g., the prescription point). Dwell times over the 50 mm active
length are optimized to cover the lateral cylinder-surface uni-
formly along the irradiated length with no consideration for dose
uniformity on the applicator dome.HDR 192Ir GYN cervical intracavitary brachytherapy
In this example, Table 2, the HR CTV D90 uncertainty for cervix
cancer treated by intracavitary HDR 192Ir BT is analyzed. The uncer-
tainty for a single fraction is different to the overall D90, which is
expressed in EQD2 for the entire treatment, consisting of EBRT plus
several fractions of BT. Delivering the dose in several fractions usu-
ally results in smaller variations due to compensating effects in
case of random uncertainties.
Assuming 4 fractions with non-systematic organ changes in-be-
tween, the uncertainties for dose delivery and interfraction varia-
tions are only half (1/
p
4) of the values stated in Example 2,
while the others stay constant as source strength calibration and
dose planning is not repeated for subsequent fractions. This would
reduce the overall uncertainty to <7%. If we further assume that in
a schedule with HDR fractions, with additional 3D imaging prior to
each fraction in order to detect anatomic variations, a 5% overall
HR CTV uncertainty is obtained.
HDR 192Ir breast balloon brachytherapy
In this example, Table 3, the relative dosimetric uncertainty is
assessed at a point on the transverse plane 10 mm from the surface
of a 50 mm diameter multi-lumen breast BT applicator (e.g., the
prescription point). The dwell position/timing optimization is com-
plex, but largely restricted to the balloon center.
LDR 125I prostate permanent brachytherapy
In this example, Table 4, the prostate D90 uncertainty is assessed
for a 50 cm3 prostate volume (post-implant CT-based on day 0)
with intraoperative treatment planning using 104 seeds spaced
with a TRUS template.
HDR 192Ir prostate US-based brachytherapy
In this example, Table 5, the relative dosimetric uncertainties
are considered with respect to the D90 and V150 dose-volume
parameters for the prostate gland (i.e., PTV).
US imaging without silicone-based stand-offs should be per-
formed for better sound coupling to rectal tissue or else there
may be D90 or V150 errors of 4% and 24%, respectively [116]. Water
or US-gel ﬁlled balloons should be used for achieving overall geom-
etry reliability of up to 1.0 mm (0.3–0.7 mm range).
A reconstruction accuracy of 0.7 mm is possible for catheters
tips when the catheter free-length measurement method (avail-
able in both Oncentra Prostate by Nucletron/Elekta and Vitesse
by Varian Medical Systems) is used [117]. Since catheter tip accu-
racy deﬁnes the accuracy of source dwell positions generated by
the TPS, this is considered as the determinative uncertainty for
catheter reconstruction for US based planning. Assuming further
a source positioning uncertainty of 1.0 mm from the afterloader
for straight catheters [50,51], the total dose calculation uncertainty
considering catheter-anatomy reconstruction can be <2% when
prostate D90, D100, V100, and V150 are considered [112]. In general,
the published data used for the treatment delivery uncertainty
cover the use of metallic catheters and representative prostate vol-
umes in the range 17–60 cm3 [109].
For each implant, it is assumed that either a single treatment
plan is generated and a single fraction is delivered, or (for the case
of delivering more fractions with the same implant) a new 3D US
image acquisition is made and a new treatment plan is calculated
based on this newly acquired image set. The procedure also re-
quires that patient remains in the same lithotomic position on
the operation table until BT delivery is ﬁnished. Additionally, the
US-probe location with the transversal detector at the base plane
remains unchanged until irradiation is complete. Any US-probe
manipulation causes further uncertainties, which are unpredict-
able and not considered in the current analysis [118]. For target
contouring uncertainty the use of US imaging is comparable to
Table 1
Example 1 – HDR 192Ir BT source for vaginal cylinder applicator.
Category Typical
level (%)
Assumptions
Source strength 2 PSDL traceable calibrations
Treatment planning 3 Reference data with the appropriate bin width
Medium dosimetric corrections 1 Valid for applicator without shielding and if CTV located inside pelvis; an advanced dose calculation
formalism should be used if this assumption false
Dose delivery including registration of
applicator geometry to anatomy
5 Accurate QA concept for commissioning and constancy checks, especially for source positioning and
applicator/source path geometry, appropriate imaging techniques (either small slice thickness, 3D
sequences or combination of different slice orientations), applicator libraries (either by using software
solutions or manual)
Interfraction/Intrafraction changes between
imaging and dose delivery
5* For one treatment plan per applicator insertion and measures to detect major variations for subsequent
fractions
Total dosimetric uncertainty (k = 1) 8 For treatment delivered with the same BT source
* Estimated value based on expert discussion.
Table 2
Example 2 – HDR 192Ir source for intracavitary, image-guided cervical cancer BT.
Category Typical
level (%)
Assumptions
Source strength 2 PSDL traceable calibrations
Treatment planning 3 Reference data with the appropriate bin width
Medium dosimetric corrections 1 Applicator without shielding and CTV inside pelvis (concerning for scatter); an advanced dose calculation
formalism should be used if this assumption false
Dose delivery including registration of
applicator geometry to anatomy
4 Accurate QA concept for commissioning and constancy checks, especially for source positioning and
applicator/source path geometry, appropriate imaging techniques (either small slice thickness, 3D
sequences or combination of different slice orientations), applicator libraries (either by using software
solutions or manual)
Interfraction/Intrafraction changes
(including contouring uncertainties)
11 For one treatment plan per applicator insertion but several subsequent fractions – if only one fraction is
applied the remaining uncertainty between imaging and dose delivery should be at least smaller than this
interfraction variation
Total dosimetric uncertainty (including
contouring uncertainties) (k = 1)
12 For treatment delivered with the same BT source – note that in cervix cancer BT, both HDR and PDR
schedules consist of several fractions, reducing the random uncertainties (see text)
Table 3
Example 3 – HDR 192Ir BT source for breast balloon applicator.
Category Typical
level (%)
Assumptions
Source strength 2 PSDL traceable calibrations
Treatment planning 3 Reference data with the appropriate bin width
Medium dosimetric corrections 3 Balloon ﬁlled with standard level of contrast agent, no consideration or composition of chestwall, lung, or
breast
Scatter dosimetric corrections 7 A non-scalar correction for skin dose (and at points in proximity to the surface near the balloon) is needed,
and will require an advanced dose calculation formalism to properly account for radiation scatter
conditions in the patient. Use of a single prescription point might be not sufﬁcient
Dose delivery including registration of
applicator geometry to anatomy
7 Accurate QA concept for commissioning and constancy checks, especially for source positioning and
applicator/ source path geometry, appropriate imaging techniques (either small slice thickness, 3D
sequences or combination of different slice orientations), applicator characterization
Interfraction/Intrafraction changes between
imaging and dose delivery
7* For one treatment plan per applicator insertion and measures to detect major variations for subsequent
fractions
Total dosimetric uncertainty (k = 1) 13 For treatment delivered with the same BT source
* Estimated value based on expert discussion.
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to CT based delineation [119].Summary
The term ‘uncertainty’ in clinical BT is related to prescribing and
reporting treatment parameters. The main parameters are dose at
certain points or dose to certain volumes. While a prescription or a
treatment plan report states these dose values, the dose actually
delivered is different for a variety of reasons. Therefore, theinteresting result of any study on uncertainties is its impact on
the estimation of the delivered dose. However, only a few types
of uncertainties (source strength and afterloader timer) are inde-
pendent of clinical disease site and location of administered dose.
Uncertainties, even for a purely water-equivalent geometry, are re-
lated to the geometry of the BT implant, in particular the source
distance to the regions of interest. These dosimetric uncertainties
are more pronounced if heterogeneous tissue composition and/or
applicator materials are considered, especially for LE sources. For
HE-sources, scatter conditions, such as for the case of skin for
breast BT, are of particular relevance. The total dose uncertainty
Table 4
Example 4 – LDR 125I sources for permanent prostate BT.
Category Typical level
(%)
Assumptions
Source strength 3 PSDL traceable calibrations
Treatment planning 4 Reference data with the appropriate bin width
Medium dosimetric corrections 5 No consideration is given for calciﬁcations or their composition in the patient
Inter-seed attenuation 4 An advanced dose calculation formalism may indicate source models and orientations cause
the largest effects
Treatment delivery imaging 2 US QA performed according to AAPM TG-128
Target contouring uncertainty 2 Using CT or CT + T2 imaging
Anatomy changes between dose delivery and post-
implant imaging
7* Post-implant imaging using CT, with a scalar correction factor for edema correction
Total dosimetric uncertainty (k = 1) 11 For treatment delivered without excreted seeds
* Estimated value based on expert discussion.
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try. Therefore, it is not possible to perform generalized quantitative
ranking of these uncertainties – only broad statements can be
made or general examples based on disease site.
One should strive to identify and minimize systematic (Type B)
uncertainties. These include the following items:
(1) Imaging uncertainties due to potential magniﬁcation or
reconstruction uncertainties. This includes global shifts and
systematic differences between the source path used for
planning and the often improperly identiﬁed source path
and source orientation during dose delivery due to inaccu-
rate 1st dwell positions or ring applicator internal cavity.
(2) Treatment planning uncertainties related to contouring the
target and OAR.
(3) Treatment planning uncertainties such as deviations of
accepted TG-43 parameters from consensus data or due to
interpolation or model simpliﬁcations. Neglect of systematic
shielding effects due to applicator materials is an error, not
an uncertainty.
(4) Dose delivery uncertainties due to temporal rounding off or
systematic offset in source positioning and dependence on
catheter curvature.
A priority ranking of uncertainties other than the above-men-
tioned systematic ones is as follows. From the ﬁndings within this
report, the largest uncertainties are at the patient level and related
to anatomical differences between the real patient situation at the
time of dose delivery and the planned patient geometry and organTable 5
Example 5 – HDR 192Ir source for temporary prostate BT.
Category Typical
level (%
Source strength 2
Treatment planning 3
Medium dosimetric corrections 1
US-based Treatment planning and delivery: Catheter reconstruction and
source positioning accuracy
2
US-based 2D and 3D-imaging overall effect 2
Changes of catheter geometry relative to anatomy between intraoperative
treatment planning and intraoperative treatment delivery
2
Target contouring uncertainty 2
Total dosimetric uncertainty (k = 1) 5deﬁnitions. Such uncertainties can become larger with increasing
time between the treatment planning imaging and dose delivery,
which is the case in fractionated treatments. However, there is
no evidence that this trend always holds true. Sometimes uncer-
tainties become smaller over time, as for example with edema res-
olution following permanent prostate BT. Additionally, there is no
evidence for GYN BT that there are larger uncertainties with PDR
than with HDR treatments.
However, here uncertainties and variations have to be distin-
guished. For speciﬁc treatment approaches, there are sometimes
systematic geometry variations, e.g., by applicator displacement
or by the target volume changes. Systematic variations due to ede-
ma or tumor shrinkage could be taken into account in the overall
dose assessment if they can be quantiﬁed accurately. In most cases,
such variations can also be visualized and tracked by imaging de-
vices or a suitable in vivo dosimetry tool and corrected. Here, we
have a strong link to resource management. How often, how accu-
rate, and with which kinds of imaging devices do we have to check
the BT treatment geometry? There is no evidence with EBRT,
including advanced procedures such as SBRT (stereotactic body
radiotherapy), that image-guidance for each individual fraction is
necessary for all disease sites. Similarly in BT, while imaging and
adaptive treatment planning seem beneﬁcial for each fraction
and for certain approaches, the consequences of dosimetric uncer-
tainties due to patient variations are not clear. If certain threshold
levels for tumor control or limitation of side effects are known, it is
possible that dose deviations of several percent will not inﬂuence
the clinical outcome (e.g., the very high doses applied within V100
for gynecological and prostate treatments). If doses are small)
Assumptions
PSDL traceable calibrations
Reference data with the appropriate bin width
Full scatter conditions in the pelvic region and for the prostate location are
assumed
Assuming usage of dedicated catheter reconstruction tools (catheter free-
length measurement based methods) for an accurate (0.7 mm)
reconstruction of catheter tip and 1.0 mm source positioning accuracy by the
afterloader for straight catheters and transfer tubes
US QA performed according to AAPM TG-128 report
Assuming that new image acquisition and treatment plan calculation is done
always before each fraction. It is also required that no manipulation of the
implant and anatomy occurs, as it is the case when removing/manipulating
the US-probe or moving the patient from the operation table before
treatment delivery
Using CT or CT + T2 imaging
For treatment delivery without patient movement and changes in the
lithotomic set-up and with the US probe at the position of the acquisition
(transversal plane at the prostate base)
210 ESTRO/AAPM report: Clinical brachytherapy uncertainty analysiscompared to those associated with side effects, uncertainties be-
yond several percentages may be ignored without major conse-
quences. Consider the example of an organ far from relevant
isodose lines compared to an organ in direct vicinity to the implant
and high doses. In addition, the spatial dose distribution could re-
main as a key element for outcome. If a certain part of a target vol-
ume is already just covered with the appropriate dose level, and
uncertainties lead to dose reduction in this speciﬁc region, the im-
pact on local control could be much higher compared to some var-
iation in the overall D90.Recommendations for uncertainty reporting
Most reports of BT uncertainties are not presented in a system-
atic manner. Clear guidelines are needed for authors presenting
their studies in the literature, and should include uncertainty esti-
mates. Every study on uncertainties in clinical BT should report its
results to allow reproduction and further comparison with other
studies. Therefore the following basic requirements are needed:
(a) Clearly distinguish between uncertainties, variations (which
can be quantiﬁed), and errors and mistakes.
(b) Quantify Type A and Type B uncertainties as outlined in the
TG-138 report, and describe the approach taken to quantita-
tively ascribe values.
(c) Use a k = 1 coverage factor for individual uncertainty compo-
nents when reporting the standard deviation in addition to
any mean value.
The study results should contain data on the analyzed parame-
ter (distance shifts, volume changes, source or applicator position,
etc.), and also be expressed with their impact on absorbed dose for
clinically-relevant dose parameters (e.g., target parameters such as
D90 or OAR dose). Additionally, this reporting should include total
dose uncertainties for the entire treatment course (including sev-
eral fractions and EBRT dose if applicable) and in terms of equi-
effective or isoeffective dose as EQD2 [66,67].
The use of EQD2 dose reporting allows no direct application of
the uncertainties related to the absorbed dose reporting. The EQD2
calculation strongly depends on the dose level due to the non-lin-
ear calculation. High dose levels with large uncertainties cause
pronounced uncertainties for EQD2 dose, with non-symmetric
deviations around the reported values. For boost treatments, the
total dose uncertainty becomes smaller compared to the uncer-
tainty of only the BT dose because it only partially contributes to
the total dose.Conclusion
Understanding the contributing factors to the overall uncer-
tainty permits uncertainty reduction and improvements in treat-
ment delivery. The ﬁeld of BT dosimetric uncertainty is an
important topic in need of additional research, combining clinical
results with a methodological assessment of how the treatment oc-
curred. With the established method on how to report BT dosimet-
ric uncertainties, attribution of resources to minimize these
uncertainties may result in improved treatment planning, patient
imaging, and treatment delivery techniques toward better inter-
institutional consistency and overall clinical outcomes.Potential conﬂicts of interest stated by the authors
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